Observed Signal · Nov 17, 2026 · Funding · Source: CNBC Technology · Impact: 4/5 · Sentiment: Positive
Isomorphic Labs raises $5 billion for AI drug discovery
Isomorphic Labs, the AI-driven drug discovery company founded by Sir Demis Hassabis, has raised a $5 billion (€4.5 billion) Series C round. Co-led by Greenoaks and Sequoia Capital, the round also saw participation from Andreessen Horowitz, Alphabet, and existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. The funding will accelerate the development of its AI drug design engine (IsoDDE), expand foundational biology models, and advance its therapeutic pipeline toward clinical trials. This investment highlights the massive capital flowing into AI-driven drug discovery, a sector that raised a record $23.2 billion in 2026. Isomorphic's round dwarfs other European AI drug discovery startups, which collectively raised approximately €148.2 million in the same period.
This large funding round highlights the growing intersection of AI and life sciences, which is a significant trend for the technology industry. While not directly adtech, it reflects the broader AI investment surge that impacts tech platforms and their capabilities.
MARKET SIGNALS
Track Isomorphic Labs Signals & Strategic Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Key Takeaways & Evidence Grounding
- Isomorphic Labs raised $5 billion (€4.5 billion) in Series C funding.
- Round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and Alphabet participating.
- Existing investors included Thrive Capital, MGX, GV, CapitalG, Temasek, and UK Sovereign AI Fund.
- Funding will advance the AI drug design engine (IsoDDE) and support pipeline progression to clinical trials.
- Drug discovery startups raised a record $23.2 billion in 2026; other European AI drug discovery startups raised €148.2 million.
Connected Companies & Entities
“Isomorphic Labs, an AI drug discovery startup founded by former Google DeepMind chief Demis Hassabis, has raised a $5 billion Series C round...”
“The round was co-led by Greenoaks and Sequoia Capital.”
“Hassabis stepped back as CEO of DeepMind, Google's AI lab, which he co-founded before the Big Tech giant acquired it in 2014.”
“The round was co-led by Greenoaks and Sequoia Capital.”
“with investment from Alphabet, Google's parent.”
“alongside Andreessen Horowitz”
“OpenAI and Anthropic have also been investing in tools to develop new medicines using the technology.”
“Anthropic announced it was launching an AI drug discovery program in June.”
“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”
“OpenAI partnered with Novo Nordisk in April.”
“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”
“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”
“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”
“participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Isomorphic Labs seeks $5B round at $50B valuation
Isomorphic Labs, Alphabet's AI drug discovery spinout led by Demis Hassabis, is reportedly in early-stage talks to raise approximately $5 billion at a valuation of around $50 billion, according to Bloomberg. This round would follow a $2.1 billion Series B in May and a $600 million round in 2025, bringing total raised to nearly $7.7 billion within 18 months. Despite the massive funding, the company has not yet tested any drug candidate in humans; clinical trials were initially planned for end of 2025, then delayed to late 2026. Investors are valuing the platform rather than a product, a record for a pre-clinical biotech. Revenue currently comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone-based payments potentially reaching up to $2.9 billion. Skepticism remains, as Eli Lilly's CEO Dave Ricks has questioned the effectiveness of AI in drug discovery, noting that protein structure prediction is just one part of the challenge.
Proximal Ventures Raises $27.5M for AI Drug Development Fund
Proximal Ventures, founded by former SignalFire investor Sahir Raoof, has raised $27.5 million for its debut venture capital fund. The fund will invest in pre-seed and seed-stage startups applying AI to drug development tools, infrastructure, and services. Proximal has already backed seven startups, including ChronicleBio, which uses AI to analyze biological and medical data for chronic disease research. The fund's backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Dimension Capital co-founders. Raoof, who previously worked at Flatiron Health and Iterative Health, aims to capture pharmaceutical spending by offering AI-driven services that are faster and cheaper than traditional outsourcing. The fund will write checks between $500,000 and $1.5 million.
London AI drug discovery startup Boltz raises $110M Series A
Boltz, a London-based AI startup focused on drug discovery, has raised a $110 million Series A funding round, less than a year after emerging from stealth. The company develops AI models to predict protein-drug interactions and design new molecules, accelerating early-stage drug discovery. The round was led by Bessemer Venture Partners, with participation from existing investors including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures, as well as new investors Greycroft, F-Prime Capital, Hummingbird, and Benchling. Nvidia had previously invested earlier this year. Boltz has announced collaborations with major pharmaceutical companies such as Pfizer, GSK, Takeda, and Bristol Myers Squibb. The funding will support further model development and investment in compute and data infrastructure.
WATCHLIST & BRIEFINGS
Receive future signals for Isomorphic Labs & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor Isomorphic Labs
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
